Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viravan Rx-to-OTC switch?

This article was originally published in The Tan Sheet

Executive Summary

PediaMed Pharmaceuticals is assessing OTC potential of its "switchable" products including its Viravan pediatric antihistamine/decongestant line, according to incoming President Cameron Durrant, MD. Durrant, whose appointment was announced Aug. 7, was VP-global business planning at Pharmacia and previously held senior positions in sales and marketing with GlaxoWellcome and Merck in the U.K. PediaMed grew from nine employees and revenue under $1 mil. in 2001 to around 75 employees and revenue in the "tens of millions" in FY 2003, according to Durrant. The new president says the firm's strengths lie in its healthy pipeline and drug delivery technology. Pediamed's only current OTC offering is Klout lice removal treatment...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel